Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Protalix BioTherapeutics (PLX) Issues Positive Update on PRX-102 Phase I/II; Improvements of Stabilization Noted
August 10, 2016 7:44 AM EDTProtalix BioTherapeutics, Inc. (NYSE: PLX) announced additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant, plant cell expressed, pegylated, modified version of the human alpha-Galactosidase-A enzyme.
We are pleased to announce additional positive results from our phase I/II Fabry clinical trial, said Moshe Manor, Protalixs President and Chief Executive Officer. The efficacy results seen to date continue to be very strong with improvements or stabilization in efficacy demonstrated across all disease parameters giving us confidence in our phase III head-to-head study... More
